Search

Editors

Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor


Connect
FCPA Blog Daily News

Entries in Eli Lilly (21)

Tuesday
May172016

Bill Steinman: The death knell tolls for hiding beneficial owners

It’s a scenario that FCPA practitioners see all too regularly. A due diligence report regarding an intermediary reveals that it’s organized not in its home jurisdiction, but in Cyprus. Or Guernsey. Or Panama.

Click to read more ...

Friday
Jun122015

Job: Counsel-Litigation and Legal Compliance (Eli Lilly, USA)

Job Title: Counsel-Litigation and Legal Compliance

Employer: Eli Lilly

Location: Indianapolis, Indiana USA

Click to read more ...

Wednesday
Apr012015

FCPA enforcement report for Q1 2015

During the first calendar quarter, there were two corporate FCPA enforcement actions -- both through SEC administrative orders -- and one individual resolution.

Click to read more ...

Tuesday
Mar032015

How do pharmas pay bribes? The SEC counts the ways

In a speech Tuesday at CBI's Annual Pharmaceutical Compliance Congress in Washington D.C., the head of the SEC's enforcement division, Andrew Ceresney, left, talked about the most common ways pharmas violate the FCPA.

Click to read more ...

Wednesday
Feb252015

Whoa! Enforcement and compliance are breaking out all over

We've talked this week about the spread of anti-corruption enforcement outside the United States. First we sampled corporate actions, and then prosecutions against individuals.

Click to read more ...

Monday
Feb232015

DOJ declination for Eli Lilly after long-running probe

Big pharma Eli Lilly said in an SEC filing Thursday that the DOJ has closed its FCPA investigation of the company.

Click to read more ...

Tuesday
Oct072014

Sanofi investigating payments in Africa, Middle East

French pharma Sanofi is investigating possible illegal payments in the Middle East and Africa from 2007 to 2012 following allegations from an anonymous whistleblower.

Click to read more ...

Monday
Mar032014

DOJ declination for Merck

Big-pharma Merck said an SEC filing Thursday that the DOJ has closed its FCPA investigation of the company.

Click to read more ...

Thursday
Dec192013

SEC annual report touts FCPA enforcement 

The U.S. Securities and Exchange Commission (SEC) published its fiscal year 2013 Agency Financial Report (AFR) to detail its financial and performance results for the President, Congress and public at large. Its purpose is portray its accomplishments and strategic goals for the next year, as well as its financial picture for budget planning. The report discusses its enforcement actions related to the FCPA in the past year, and the guidelines it provided businesses in complying with the law.

Click to read more ...

Friday
Oct182013

U.S., China enforcement crossfire creates new risks

At the beginning of this year, China's president Xi Jinping promised to fight both "tigers" and "flies" -- high-ranking and low-ranking corrupt officials -- in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.

Click to read more ...

Wednesday
Sep042013

Bribery part of GSK business plan, China police say

Image courtesy of GlaxoSmithKlineA police investigation in China has found that drugmaker GlaxoSmithKline's alleged bribery of doctors ‘was coordinated by the British company and was not the work of individual employees,’ according to a report Tuesday by Reuters.

Click to read more ...

Monday
Aug262013

Drug sellers ‘take vacations’ amid China anti-graft campaign 

Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.

Click to read more ...